Tag: Opdivo
Nivolumab Rx Beyond Progression Beneficial in Melanoma
28 percent of patients treated beyond progression had lesion reduction >30 percent
AACR: Five-Year Survival 16 Percent With Nivolumab in NSCLC
Of the 16 patients who survived at least five years, nine were male, 12 were current smokers at baseline
Myocarditis ID’d With Ipilimumab + Nivolumab in Melanoma
Case report describes two patients who developed fatal T-cell-driven drug reaction
Nivolumab Ups Overall Survival in Head, Neck Cancer
Longer overall survival compared with single-agent therapy for platinum-refractory squamous-cell cancer
Favorable Outcomes for Vitiligo in Nivolumab-Treated Melanoma
Patients with vitiligo had higher objective response rate; prolonged progression-free, overall survival
